These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15107971)

  • 21. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
    J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.
    Lorber MI; Ponticelli C; Whelchel J; Mayer HW; Kovarik J; Li Y; Schmidli H
    Clin Transplant; 2005 Apr; 19(2):145-52. PubMed ID: 15740547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression.
    Gentil MA; González-Roncero F; Cantarell C; López M; Marco J
    Transplant Proc; 2005 Apr; 37(3):1441-2. PubMed ID: 15866631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
    Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
    Potena L; Bianchi IG; Magnani G; Masetti M; Coccolo F; Fallani F; Russo A; Grigioni F; Branzi A; Ponticelli C
    Transplantation; 2010 Jan; 89(2):263-5. PubMed ID: 20098293
    [No Abstract]   [Full Text] [Related]  

  • 26. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
    Sheshgiri R; Gustafsson F; Sheedy J; Rao V; Ross HJ; Delgado DH
    J Heart Lung Transplant; 2009 Nov; 28(11):1193-7. PubMed ID: 19783164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
    Nashan B
    Transplant Proc; 2001; 33(7-8):3215-20. PubMed ID: 11750380
    [No Abstract]   [Full Text] [Related]  

  • 30. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
    Gustafsson F; Barth D; Delgado DH; Nsouli M; Sheedy J; Ross HJ
    Eur J Clin Pharmacol; 2009 Jul; 65(7):659-65. PubMed ID: 19458944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients.
    Schweiger M; Stiegler P; Puntschart A; Sereinigg M; Prenner G; Wasler A; Tscheliessnigg K
    Exp Clin Transplant; 2012 Jun; 10(3):273-7. PubMed ID: 22631065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of a trial comparing sirolimus plus mycophenolate mofetil versus sirolimus plus cyclosporine.
    Ponticelli C; Tarantino A; Aroldi A; Sparacino V; Stefoni S; Citterio F; Duca L; Scolari MP; Calabrese S; Altieri P; Civati G; Cesana B
    Transplant Proc; 2003 May; 35(3 Suppl):62S-63S. PubMed ID: 12742469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C; Croom KF
    Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients.
    Khosroshahi HT; Asghari A; Estakhr R; Baiaz B; Ardalan MR; Shoja MM
    Transplant Proc; 2006 Sep; 38(7):2077-9. PubMed ID: 16980004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J; Ross H; Bara C; Delgado JF; Dengler T; Lehmkuhl HB; Wang SS; Dong G; Witte S; Junge G; Potena L
    Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.